FIEBRE aims to design new evidence-based guidelines to manage fever, thereby ensuring that patients get drugs that give them the best chance of recovery, and thereby help stop the spread of antimicrobial resistance (AMR), a major global health problem.
Research led by the Centre for Tropical Medicine and Global Health, involving a new finger-prick blood test (C-reactive protein) to help nurses and doctors decide whether their patients need antibiotic treatment. A superbug crisis has arisen because microbes are becoming increasingly resistant to antibiotics and other antimicrobials. Yet, patients’ lifestyles, cultural beliefs around illness and treatment, and the vast diversity of public, private, and unregulated healthcare providers were common barriers to accessing or correctly understanding the test.
The Structural Genomics Consortium Oxford is leading a new open-access platform to generate novel high-quality reproducible and renewable antibodies for both established and novel ALS genes and variants. Working in partnership with the ALS Association (US), the Motor Neurone Disease Association (UK) and the ALS Society of Canada, the SGC labs at the University of Oxford, Karolinska Institutet and Montreal Neurological Institute will jointly generate up to 75 novel renewable, fully validated high-quality antibodies for up to 45 novel ALS-associated genes (and variants).
Science Blog. Professor Guy Thwaites, Director of the Oxford University Clinical Research Unit, Vietnam, explains the discovery of yet another use for one of the most ubiquitous and ancient of drugs – aspirin. Aspirin is a commonly available over-the-counter medication that prevents blood clotting and helps reduce and resolve inflammation. Our research team in Vietnam wondered whether this ancient drug might help increase survival rates from TB meningitis by reducing brain inflammation and preventing the disease from blocking blood vessels in the brain that cause parts of the brain to die (commonly called ‘stroke’).
The 'Settlers' exhibition has opened at the Oxford University Museum of Natural History. Based on WHG research, this interactive exhibition tells the story of Britain's ever changing population as revealed by genetics, archaeology and demography.
Researchers recently used DNA from the 10,000-year-old “Cheddar Man”, one of Britain’s oldest skeletons, to unveil what the first inhabitants of what now is Britain actually looked like. A recent article in The Conversation with Oxford Big Data Institute's George Busby explains how DNA from old skeletons has provided intriguing findings about our ancestors and how rapid advances in genetic sequencing over the past few decades have opened up a whole new window into the past.
Health Data Research UK is awarding £30 million funding to six sites across the UK, including the University of Oxford, to address challenging healthcare issues through use of data science. Professor Martin Landray, Director of the Health Data Research UK Oxford site said: 'We are delighted that the Big Data Institute at University of Oxford will play a major part in Health Data Research UK. This exciting endeavour brings new opportunities to understand the causes of disease and to develop new treatments with substantial benefits for patients and public health.'
Vaccitech, an Oxford University spinout company developing a universal flu vaccine has secured £20 million in Series A financing. The round was co-led by new investors GV, Sequoia China, and existing backer Oxford Sciences Innovation, which manages a £600m fund aimed at Oxford University spinouts, and was also joined by Neptune Ventures. This brings the total amount raised by Vaccitech to £30 million since it was established in 2016. Vaccitech is commercialising the research of vaccine development specialists Adrian Hill and Sarah Gilbert, who developed the underpinning technology at the Jenner Institute.
If you have news or events that you would like to be added to this website, please email us details. If possible, please include a picture and links to further information.